JommiC., and CavazzaM. “Management of Patients Eligible for Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals”. Global & Regional Health Technology Assessment, Vol. 6, no. 1, July 2019, doi:10.33393/grhta.2019.460.